(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)
Tokyo, October 30, 2015 - Astellas Pharma Inc. (Tokyo:4503, President and CEO: Yoshihiko Hatanaka, hereinafter called 'the Company') announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares under Article 156 which is
applicable in accordance with Article 165, paragraph 3 of the Companies Act.
Particulars
Reasons for the acquisition of own shares
To improve capital efficiency and shareholder return.
Contents of acquisition
Class of shares to be acquired: Common stock of the Company
Total number of shares to be acquired: Up to 16 million shares
(The percentage compared to the total number of shares outstanding: 0.74 %)
Aggregate amount of acquisition cost: Up to 30 billion yen
Period of acquisition: From November 2, 2015 to December 18, 2015 (Reference)
The status of treasury shares as of September 30, 2015:
Total number of shares outstanding: 2,157,802,942 shares Number of treasury shares: 64,020,233 shares
######
For inquiries or additional information Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201, FAX:+81-3-5201-7473
http://www.astellas.com/en
distributed by |